Cynapsus
Toronto, CA · 1 known investors
Find your way into Cynapsus
Cynapsus is a specialty central nervous system pharmaceutical company developing a fast-acting sublingual thin film for on-demand management of OFF episodes in Parkinson's disease patients. Its lead candidate, APL-130277, is a sublingual formulation of apomorphine intended as an alternative to subcutaneous injection, and had entered Phase 3 clinical development.
Founders & leadership
AG
Anthony GiovinazzoFounder
AW
Andrew WilliamsExecutive
TB
Thierry BilbaultExecutive
NB
Nathan BrysonExecutive
Board
IO
Ilan OrenBoard director
TG
Tomer GoldBoard director
MN
Margaret Nan HutchinsonBoard director
TD
Tamar D. HowsonBoard director
RH
Ronald HoskingBoard director
RS
Rochelle StenzlerBoard director
PM
Perry MolinoffBoard director
AT
Alan TorrieBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$32.2M disclosed across 3 rounds · 2011–2015
▶$16.8MraisedApr 2015 · 14 investors · PharmaceuticalsRule 506(b)
▶$16.8MraisedApr 2015 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Margaret Nan HutchinsonDirector
- Andrew WilliamsExecutive Officer
- Anthony GiovinazzoExecutive Officer, Director
- Thierry BilbaultExecutive Officer
- Tamar D. HowsonDirector
- Ronald HoskingDirector
- Rochelle StenzlerDirector
- Ilan OrenDirector
- Tomer GoldDirector
- Perry MolinoffDirector
- Offering amount
- $16.8M
- Amount sold
- $16.8M
- Sales commissions
- $1M
- Placement agents
- Noble Financial Capital Markets
- First sale
- Mar 2015
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$14.5MraisedApr 2014 · 19 investors · PharmaceuticalsRule 506(b)
▶$14.5MraisedApr 2014 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Perry MolinoffDirector
- Nan HutchinsonDirector
- Anthony GiovinazzoExecutive Officer, Director
- Rochelle StenzlerDirector
- Alan D. C. RyleyDirector
- Tomer GoldDirector
- Ilan OrenDirector
- Andrew WilliamsExecutive Officer
- Ronald HoskingDirector
- Offering amount
- $42.9M
- Amount sold
- $14.5M
- Sales commissions
- $1M
- Placement agents
- Brookline Group, LLC, Noble Financial Capital Markets
- First sale
- Apr 2014
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$939.5KraisedMar 2012 · 7 investors · PharmaceuticalsRule 506(b)
▶$939.5KraisedMar 2012 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nathan BrysonExecutive Officer
- Anthony GiovinazzoExecutive Officer
- Alan TorrieDirector
- David HillDirector
- Ronald HoskingDirector
- Julia LevyDirector
- Andrew WilliamsExecutive Officer
- Alan RyleyDirector
- Rochelle StenzlerDirector
- Offering amount
- $939.5K
- Amount sold
- $939.5K
- Sales commissions
- $38.3K
- Placement agents
- Summer Street Research Partners
- First sale
- Sep 2011
- Incorporated
- Corporation, Ontario, Canada
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Cynapsus do?
- Cynapsus is a specialty central nervous system pharmaceutical company developing a fast-acting sublingual thin film for on-demand management of OFF episodes in Parkinson's disease patients. Its lead candidate, APL-130277, is a sublingual formulation of apomorphine intended as an alternative to subcutaneous injection, and had entered Phase 3 clinical development.
- Who founded Cynapsus?
- Cynapsus was founded by Anthony Giovinazzo.
- Who are Cynapsus's investors?
- Cynapsus's investors include Aisling Capital.
- How much funding has Cynapsus raised?
- Cynapsus has disclosed $32.2M raised across 3 rounds.
- Where is Cynapsus headquartered?
- Cynapsus is headquartered in Toronto, CA.